Human beta-defensin chimeric peptides
This invention exploits the remarkable differences in the antimicrobial properties shown by human beta-defensins 2 and 3 (HBD2 and HBD3) against Gram-positive and Gram-negative bacteria through the generation of chimeric molecules of HBD2 and HBD3 with improved activity against E.coli and S.aureus strains compared to wild-type. The chimeras are very interesting novel molecules, based on the natural human proteins, which offer a combined and improved defensin activity.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…
